Unresectable
1
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
Recursion PharmaceuticalsREC-1245
Innovent BiologicsIBI3005
Clinical Trials (2)
Total enrollment: 283 patients across 2 trials
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Start: Nov 2024Est. completion: Oct 202885 patients
Phase 1/2Recruiting
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Start: Jan 2025Est. completion: Dec 2027198 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 283 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.